Elevated Admission Plasma Glucose Following ACS

Background

Trial Design

MACE After 180 Days Based on Admission Glucose Levels

Conclusions

Long-Term Secondary Prevention With Ticagrelor

Background

Primary Endpoint by History of Coronary Stent Composite of CV Death, MI, or Stroke

Safety Endpoints Bleeding According to Prior Stenting

All-Cause Mortality

Conclusions

Patient Selection for Long-Term Secondary Prevention With Ticagrelor

PEGASUS-TIMI 54 Ticagrelor in Patients With Prior MI

Optimizing Treatment Through Patient Selection

Derivation of Risk Score

Patient Selection Algorithm

Summary

Potential Impact of the Latest Data in Clinical Practice

3 Key Studies in Patients With ACS

Summary and Clinical Implications

Abbreviations